David J. Liewehr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David J. Liewehr has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- William Douglas Figg
Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, USA
49 shared publications - Amy James
Animal research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
48 shared publications - Angela Kim
Department of Pathology and Molecular Medicine, Yale School of Medicine, New Haven, Connecticut
48 shared publications - Angelina V. Vaseva
Oregon Health and Science University 7 Department of Pediatrics, Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute Portland, Oregon
48 shared publications - Christina M. Robinson
Frederick National Laboratory for Cancer Research 3 Frederick, MD
48 shared publications - Cody J. Peer
Center for Cancer Research, NCI, Bethesda, Maryland, United States
48 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Combining ganitumab with trametinib inhibits tumor growth and increases fibrosis in SMS-CTR but not RD xenografts
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Combining ganitumab with trametinib inhibits tumor growth and increases fibrosis in SMS-CTR but not RD xenografts
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Pharmacodynamic response to trametinib/ganitumab in xenograft models does not predict tumor shrinkage
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Pharmacodynamic response to trametinib/ganitumab in xenograft models does not predict tumor shrinkage
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
The combination of trametinib and ganitumab does not induce hyperinsulinemia or hematologic adverse events in SCID beige mice
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
The combination of trametinib and ganitumab does not induce hyperinsulinemia or hematologic adverse events in SCID beige mice
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Effect of trametinib and ganitumab in additional cell culture models of RAS-mutated RMS
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Effect of trametinib and ganitumab in additional cell culture models of RAS-mutated RMS